Aug 24, 2023Alpha Tau Medical to Participate in September Investor ConferencesJERUSALEM, August 24, 2023 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...
Aug 21, 2023Alpha Tau Announces Robust Long-Term Safety and Efficacy Data from Multiple Clinical Trials of Alpha- 81 lesions treated across four feasibility trials of head and neck or skin cancers demonstrated 89% complete response rate. - Two-year...
Aug 2, 2023Alpha Tau Medical to Present at the Emerging Growth Conference on August 9th, 2023JERUSALEM, August 02, 2023 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...
May 25, 2023Alpha Tau Medical to Participate in June Investor ConferencesJERUSALEM, May 24, 2023 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative...
May 24, 2023Alpha Tau Medical Announces First Quarter 2023 Financial Results and Provides Corporate Update- Opened U.S. multicenter pivotal trial in recurrent cutaneous skin cancer, which began enrolling patients in March - - Treated the first...